Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib rollover study for ALK-positive malignancies after prior Novartis-sponsored ceritinib trials
2015-001922-40Phase 4Active
- Sponsor
- Novartis
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ceritinib in non-small cell lung cancer (NSCLC) and Anaplastic Large Cell Lymphoma ALK-positive, sponsored by Novartis. Primary endpoint: Number of patients receiving ceritinib. Started Oct 2015; status: active.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)Anaplastic Large Cell Lymphoma ALK-positive
Beyond the preview
Go deeper on 2015-001922-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001922-40.